Healthcare firm Biote Q2 revenue misses expectations

Reuters
08/07
Healthcare firm Biote <a href="https://laohu8.com/S/QTWO">Q2</a> revenue misses expectations

Overview

  • Biote Q2 2025 revenue misses analyst expectations, per LSEG data

  • Net income rises to $3.9 mln, driven by dietary supplement sales

  • Company initiated reorganization to boost clinic and procedure growth

Outlook

  • Biote revises 2025 revenue guidance to above $190 mln

  • Company expects 2025 adjusted EBITDA above $50 mln

  • Biote sees 2025 procedure revenue decreasing at high single-digit rate

  • Company forecasts 2025 dietary supplement revenue to grow at mid-teens rate

Result Drivers

  • DIETARY SUPPLEMENT SALES - Increased 30.4% year-over-year, contributing positively to revenue

  • GROSS MARGIN EXPANSION - Improved to 71.6% due to vertical integration and cost management

  • REORGANIZATION - Initiated restructuring to enhance productivity and drive long-term success

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$48.90 mln

$49.50 mln (5 Analysts)

Q2 EPS

$0.1

Q2 Adjusted EBITDA

$15.20 mln

Q2 Gross Margin

71.6%

Q2 Adjusted EBITDA Margin

31.1%

Q2 Operating Income

$10.80 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the professional information services peer group is "buy"

  • Wall Street's median 12-month price target for Biote Corp is $7.00, about 40.4% above its August 5 closing price of $4.17

  • The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nBw4Pl6kya

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10